Mobilization of PBSCs in poor mobilizers with POEMS syndrome using G-CSF with plerixafor

Bone Marrow Transplantation

Volumn 47, Issue 12, 2012, Pages 1587-1588

  Shimizu, N ^a   Sakaida, E ^a   Ohwada, C ^a   Takeuchi, M ^a   Kawaguchi, T ^a   Tsukamoto, S ^a   Sakai, S ^a   Takeda, Y ^a   Sugita, Y ^a   Yokote, K ^b   Iseki, T ^a   Isose, S ^b   Kanai, K ^b   Misawa, S ^b   Kuwabara, S ^b   Nakaseko, C ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PLERIXAFOR; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; THALIDOMIDE;

ADULT; ASCITES; CASE REPORT; CD34 SELECTION; DRUG DOSE REDUCTION; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; LYMPHOMA; MALE; MYELOMA; NEUROPATHY; PERIPHERAL BLOOD STEM CELL; PLEURA EFFUSION; POEMS SYNDROME; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SYMPTOMATOLOGY;

ADULT; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POEMS SYNDROME;

EID: 84870773698     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.80     Document Type: Letter

References (10)

1. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009; 77: 1655-1664.
2. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730.
3. Kobold S, Isernhagen J, Hubel K, Kilic N, Bogner C, Frickhofen N et al. Plerixafor is effective and safe for stem cell mobilization in heavily pretreated germ cell tumor patients. Bone Marrow Transplant 2011; 46: 1053-1056.
4. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
5. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
6. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241-249.
7. Dispenzieri A, Moreno-Aspitia A, Suarez GA, Lacy MQ, Colon-Otero G, Tefferi A et al. Peripheral blood stem cell transplantation in 16 patients with POEMS syndrome, and a review of the literature. Blood 2004; 104: 3400-3407.
8. Kuwabara S, Misawa S, Kanai K, Suzuki Y, Kikkawa Y, Sawai S et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology 2008; 71: 1691-1695.
9. Perea G, Sureda A, Martino R, Altes A, Martinez C, Cabezudo E et al. Predictive factors for a successful mobilization of peripheral blood CD34\+ cells in multiple myeloma. Ann Hematol 2001; 80: 592-597.
10. Shimizu N, Nakaseko C, Sakaida E, Ohwada C, Takeuchi M, Kawaguchi T et al. Factors associated with the efficiency of PBSC collection in POEMS syndrome patients undergoing autologous PBSC transplantation. Bone Marrow Transplant 2012; 47: 1010-1012